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Abstract
The role of induction chemotherapy in nasopharyngeal carcinoma (NPC) remains 
controversial. The primary aim of this study was to use the National Cancer Database 
to evaluate the patterns of care of induction chemotherapy in NPC and its impact on 
overall survival (OS). Patients with NPC from 2004 to 2014 were obtained from the 
NCDB. Patients were considered to have received induction chemotherapy if it was 
started ≥43 days before the start of RT and concurrent CRT if chemotherapy started 
within 21 days after the start of RT. Propensity score matching was used to control 
for selection bias. Cox proportional hazards model was used to determine significant 
predictors of OS. Logistic regression model was used to determine predictors of the 
use of induction chemotherapy. Significance was defined as a P value <.05. A total 
of 4857 patients were identified: 4041 patients (87.2%) received concurrent CRT and 
816 patients (16.8%) received induction chemotherapy. The use of induction therapy 
remained stable between 2004 and 2014. Younger patients and those with higher T- 
and N- stage had a higher likelihood of being treated with induction chemotherapy. 
The 5- year OS in patients treated with induction chemotherapy and CRT was 66.3% 
vs 69.1%, respectively (P = .25). There was no difference in OS when these two 
groups were analyzed after propensity score matching. No differences in OS existed 
between these treatment groups in patients with T3- T4N1 or TanyN2- 3 disease 
(P = .76). Propensity score matching also did not reveal any difference in OS in pa-
tients with T3- T4N1 or TanyN2- 3 disease. The use of induction chemotherapy has 
remained stable in the last decade. In this study of patients with NPC, induction 
chemotherapy was not associated with improved OS compared to CRT alone.
K E Y W O R D S
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1 |  INTRODUCTION
Nasopharyngeal carcinoma (NPC) accounts for approxi-
mately 3000 new cases in the United States each year and 
approximately 80 000 new cases worldwide, with the 
majority of them diagnosed in Southeast and Eastern Asia, 
and Northern Africa.1 Given its anatomical location and the 
proximity to critical organs, radiation therapy (RT) is the pri-
mary local modality in contrast to other head and neck ma-
lignancies where surgery may still play a major role. As such, 
prior to the advent of megavoltage RT, NPC had a poor prog-
nosis; however, modern RT technology, especially Intensity 
Modulated RT, and concurrent chemotherapy has resulted in 
>70% 5- year overall survival.2-5
Several studies in the early 1990s and 2000s demonstrated 
that concurrent chemoradiation (CRT) followed by adjuvant 
cisplatin improved survival compared to RT alone and es-
tablished this as the standard of care for newly diagnosed 
NPC.2,5 Furthermore, the use of 3- dimensional imaging (CT 
and MRI) along with improvement in RT technology has re-
sulted in excellent local control rates.6 However, distant fail-
ure still remains the main source of mortality in this patient 
population. There is a notion that additional chemotherapy, 
either in the form of induction therapy or adjuvant therapy, 
may improve distant control, especially in patients with lo-
cally advanced disease, resulting in an improved overall 
survival.
There have been several studies that have evaluated addi-
tional cycles of chemotherapy in the adjuvant setting without 
finding significant survival benefit.5,7 The primary limita-
tion of the preceding trials has been a low compliance rate 
of adjuvant chemotherapy with approximately 40- 50% pa-
tients not completing the prescribed chemotherapy regimen.7 
Alternatively, induction chemotherapy is thought to be better 
tolerated and may result in early eradication of micrometas-
tasis, leading to the hypothesis that it may result in improved 
survival. However, this has been controversial as several 
studies have found a survival benefit with this approach, 
while others have not.8-10 A meta- analysis based on individ-
ual patient data has showed no benefit with induction chemo-
therapy.11 In this study, we aim to use the National Cancer 
Database (NCDB) to study the patterns of care in the use of 
induction chemotherapy and evaluate the survival benefit of 
induction chemotherapy in NPC.
2 |  MATERIALS AND METHODS
The NCDB is a joint project of the American Cancer Society 
and the American College of Surgeons Commission on 
Cancer. The American College of Surgeons has executed 
a Business Associate Agreement that includes a data use 
agreement with each of its Commission on Cancer accredited 
hospitals. The NCDB, established in 1989, is a nationwide, 
facility- based, comprehensive clinical surveillance resource 
oncology data set that currently captures 70% of all newly 
diagnosed malignancies in the US annually. Data elements 
are collected and submitted to the NCDB from commission- 
accredited oncology registries using standardized coding and 
data item definitions, including details not available from the 
Surveillance, Epidemiology, and End Results (SEER) reg-
istry, such as RT dose/technique, chemotherapy use/timing, 
and comorbidities.12
De- identified data for patients with newly diagnosed 
NPC from 2004 to 2014 were obtained from the NCDB 
participant user file. Inclusion and exclusion criteria are 
summarized in the CONSORT diagram (Figure 1A). Of the 
14 600 patients identified, 4857 were included in the final 
analysis. Patients were considered to have received induc-
tion chemotherapy if it was started ≥43 days before the start 
of RT. This time point was chosen as it would allow for ad-
ministration of 2- 3 cycles of induction chemotherapy used in 
recent trials.7,8,10 Patients were considered to have received 
concurrent CRT if chemotherapy started within 21 days 
after the start of RT as this would allow for overlap of at least 
2- 3 cycles of concurrent chemotherapy with RT. Patients not 
meeting this criteria for induction and concurrent chemo-
therapy were excluded. It is also important to mention here 
that the use of adjuvant chemotherapy after completion of 
concurrent CRT could not be determined in this study due 
to the limitations of the database. To account for the im-
mortal time bias, patients with <6 months of follow- up or 
those who died <6 months after diagnosis were excluded. 
The 6 month time frame was chosen as it would allow all 
definitive treatment to be completed.
Given that a definitive RT dose for NPC in most recent 
trials is 70 Gy,8,13 we categorized patients as those receiving 
<70 Gy or ≥70 Gy. For the purpose of this categorization, 
patients receiving 69.96 Gy were considered to have received 
70 Gy since 69.96 Gy is also considered to be a definitive 
RT dose for NPC. Of note, multiple RT dose levels including 
69, 68, 67, and 66 Gy were also analyzed and the results of 
this study remained unchanged (Figure S1). Other variables 
were categorized as previously published by Seisen et al14. 
Insurance and education variables were categorized into high 
and low, referring to the highest two quartiles and the lowest 
two quartiles, respectively.
Categorical data were summarized by frequency counts 
and percentages. Continuous variables were compared using 
the Wilcoxon test, and categorical variables were compared 
using Fisher’s exact test. The primary end point was overall 
survival (OS), which was defined as the time from the date of 
their diagnosis to the date of death. OS rates were determined 
using the Kaplan- Meier method and were compared between 
groups using log- rank statistics. The Cox proportional haz-
ards model was used to determine significant predictors of 
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OS and to estimate hazard ratios (HRs) as well as associated 
95% confidence intervals (CI). Logistic regression model 
was used to determine significant predictors of the use of in-
duction chemotherapy and to estimate odds ratio (OR) as well 
as the associated 95% CI. Variables were included in the mul-
tivariable analysis only if significant on univariable analysis.
To reduce selection bias in this study, methods used by 
Seisen et al14 in their recent NCDB publication were utilized. 
Briefly, to account for selection bias, observed differences in 
baseline characteristics between the complete cases of the two 
groups were controlled for with inverse probability of treat-
ment weighting (IPTW)- adjusted analysis. The goodness- of- 
fit statistic of the propensity score model, including linear or 
nonlinear covariates categorized with clinically relevant cut-
offs, was assessed using the method described by Lemeshow 
and Hosmer.15 Covariate balance was evaluated using the 
standardized difference approach and Kernel density plots 
(Figure S2). Statistical analyses were performed using SPSS, 
Version 23, and R, Version 3.3.2. Significance was defined as 
a P value <.05. All statistical tests were two sided.
3 |  RESULTS
A total of 4857 patients were included in the analysis based 
on the previously mentioned selection criteria: 4041 patients 
(87.2%) received concurrent CRT and 816 patients (16.8%) re-
ceived induction chemotherapy (Table 1). There were several 
differences in patient characteristics that were identified be-
tween the two groups. Patients who received induction therapy 
were identified to be younger, had higher T- stage and N- stage, 
and received <70 Gy RT dose. More patients in the CRT alone 
group were treated with ≥70 Gy (60.2% vs 54.4%, P = .01).
The utilization of induction chemotherapy has re-
mained stable between 2004 and 2014, ranging between 
13.2% and 22.1% (Figure 1B). Correlates for the receipt 
F I G U R E  1  A, CONSORT diagram. 
B, Trends in the utilization of induction 
chemotherapy in nasopharyngeal carcinoma
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of induction chemotherapy were determined using uni-
variable and multivariable modeling (Table 2). On uni-
variable analysis, it was found that patients who were 
younger, had Medicaid or were uninsured, had lower edu-
cation, and had T4 or N3 disease had a higher likelihood 
of receiving induction chemotherapy. Additionally, pa-
tients who received induction chemotherapy had a higher 
likelihood of being treated with <70 Gy. On multivari-
able analysis, patients with lower education (OR 1.35, 
95% CI 1.08- 1.68, P = .01), T4 disease (OR 1.90, 95% 
CI 1.46- 2.48, P < .001), N3 disease (OR 2.47, 95% CI 
1.72- 3.56, P < .001), and patients receiving <70 Gy RT 
(OR 1.28, 95% CI 1.05- 1.55, P = .02) had a higher likeli-
hood of being treated with induction therapy. Conversely, 
older patients (OR 0.98, 95% CI 0.97- 0.99, P < .001) had 
a lower likelihood of being treated with induction therapy 
(Table 3).
At the time of analysis, 1566 patients (32.2%) had died. 
The median follow- up time was 45 (6.0- 154.7) months. On 
univariable analysis, factors associated with improved OS 
were younger age, lower Charlson- Deyo Comorbidity Index 
(CDCI), “Other” race, patients with private insurance, higher 
education and income level, lower T- and N- stage, and pa-
tients receiving ≥70 Gy RT (Table 3). On multivariable 




P- valuen = 4041 (%) n = 816 (%)
Age
Mean (SD) 53.9 (13.3) 51.1 (13.6) <.001
Sex
Male 2842 (70.3) 619 (75.9) .007
Female 1199 (29.7) 197 (24.1)
Year of diagnosis
2004 259 (6.4) 44 (5.4) .007
2005 308 (7.6) 47 (5.8)
2006 299 (7.4) 54 (6.6)
2007 332 (8.2) 78 (9.6)
2008 326 (8.1) 70 (8.6)
2009 360 (8.9) 81 (9.9)
2010 394 (9.8) 112 (13.7)
2011 400 (9.9) 87 (10.7)
2012 410 (10.1) 87 (10.7)
2013 469 (11.6) 80 (9.8)
2014 484 (12.0) 76 (9.3)
Charlson/Deyo score
0 3488 (86.3) 709 (86.9) .57
1 448 (11.1) 91 (11.2)
2 105 (2.6) 16 (2.0)
Race
White 2505 (62.7) 514 (63.5) .008
African 
American
534 (13.4) 134 (16.6)
Other 956 (23.9) 161 (19.9)
Facility type
Academic 1528 (43.7) 287 (43.0) .73
Non Academic 1969 (56.3) 381 (57.0)
Facility location
East 1568 (44.8) 298 (44.6) .06
Central 1277 (36.5) 268 (40.1)
West 652 (18.6) 102 (15.3)
Insurance status
Private 2253 (56.6) 425 (53.2) <.001
Medicaid or 
other Govt
600 (15.1) 165 (20.7)
Medicare 889 (22.3) 136 (17.0)
Uninsured 240 (6.0) 73 (9.1)
Education level
High 2108 (52.6) 381 (47.0) .004





P- valuen = 4041 (%) n = 816 (%)
Income level
High 2326 (58.0) 454 (56.0) .29
Low 1683 (42.0) 357 (44.0)
County type
Metro 3381 (85.9) 668 (83.9) .07
Urban 506 (12.9) 111 (13.9)
Rural 47 (1.2) 17 (2.1)
Clinical T stage
T1 1084 (26.8) 176 (21.6) <.001
T2 1192 (29.5) 191 (23.4)
T3 774 (19.2) 159 (19.5)
T4 991 (24.5) 290 (35.5)
Clinical N stage
N0 844 (20.9) 150 (18.4) <.001
N1 1281 (31.7) 219 (26.8)
N2 1591 (39.4) 332 (40.7)
N3 325 (8.0) 115 (14.1)
RT dose
≥7000 cGy 2447 (60.6) 441 (54.0) .001
<7000 cGy 1594 (39.4) 375 (46.0)
T A B L E  1  (Continued)
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T A B L E  2  Univariable and multivariable analysis on factors predictive for receipt of induction chemotherapy
Univariable analysis Multivariable analysis
OR (95% CI) P- value OR (95% CI) P- value
Age
Continuous 0.98 (0.98- 0.99) <.001 0.98 (0.97- 0.99) <.001
Sex
Male Ref Ref
Female 0.75 (0.63- 0.90) .001 NS
Year of diagnosis
2004 Ref Ref
2005 0.90 (0.56- 1.40) .64 NS
2006 1.06 (0.69- 1.64) .78 NS
2007 1.38 (0.92- 2.07) .12 NS
2008 1.26 (0.84- 1.91) .26 NS
2009 1.32 (0.89- 1.98) .17 NS
2010 1.67 (1.14- 2.45) .008 NS
2011 1.28 (0.86- 1.90) .22 NS
2012 1.25 (0.84- 1.85) .27 NS
2013 1.00 (0.67- 1.50) .98 NS
2014 0.92 (0.62- 1.38) .70 NS
Charlson index
0 Ref Ref
1 1.00 (0.79- 1.27) .99 NS
2 0.75 (0.44- 1.28) .29 NS
Race
White Ref Ref
African American 1.22 (0.99- 1.51) .06 NS
Other 0.81 (0.68- 0.99) .04 NS
Facility type
Academic Ref Ref
Non Academic 1.03 (0.87- 1.22) .73 NS
Facility location
East Ref Ref
Central 1.10 (0.92- 1.32) .28 NS
West 0.82 (0.65- 1.05) .12 NS
Insurance status
Private Ref Ref
Medicaid or Other Govt 1.46 (1.19- 1.78) <.001 NS
Medicare 0.81 (0.66- 1.00) .05 NS
Uninsured 1.61 (1.22- 2.14) .001 NS
Education level
High Ref Ref
Low 1.25 (1.08- 1.45) .004 1.35 (1.08- 1.68) 0.01
Income level
High Ref Ref
Low 1.09 (0.93- 1.26) .28 NS
(Continues)
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analysis, young age, lower CDCI, “Other” race, private insur-
ance, lower T- and N- stage, and RT dose ≥70 Gy remained 
independent predictors of OS (Table 3). The 5- year OS in 
patients receiving ≥70 Gy was 69.6% vs 67.2% in patients 
receiving <70 Gy (Figure 2, P < .01).
Induction chemotherapy was not found to be associated 
with survival on either univariable or multivariable analysis. 
The 5- year OS in patients who received induction chemo-
therapy was 66.3% vs 69.1% in patients who received con-
current CRT alone (Figure 3A, P = .25). To minimize the 
selection bias towards the use of induction chemotherapy, as 
well as to minimize the differences in patient characteristics 
between the two groups, patients in the induction group were 
matched to patients in the concurrent CRT alone group using 
propensity score matching. In the matched cohort, the 5- year 
OS was not statistically different between the two groups 
(Figure 3B, P = .91). A subset analysis in patients with high 
risk disease, defined as T3- T4N1 or TanyN2- 3, was also con-
ducted (Figure 3C). There were 2502 patients in the CRT 
alone group and 454 in the induction group. No differences 
in 5- year OS was noted between the patients who received 
induction chemotherapy vs concurrent CRT alone in this high 
risk cohort (Figure 3C, P = .76). Patients in the high risk 
cohort were also matched using propensity score matching, 
and no difference in OS was noted between the two groups 
(Figure 3D, P = .64). When stratifying by individual T- stage 
and N- stage, induction therapy was not found to be associ-
ated with improved OS (Figure S3). Additionally, a subset 
analysis was performed on cases where detailed histological 
information was available (WHO Type 1 vs WHO Type 2/3). 
A total of 1255 cases were identified of which 260 (20.7%) 
were WHO I and 995 (79.3%) were WHO II/III. Induction 
therapy was not found to be associated with improved OS 
with either types of histology (Figure S4).
4 |  DISCUSSION
The results of this large cohort study show that the use of in-
duction therapy in NPC has remained stable between 2004 
and 2014. When compared with concurrent CRT alone, in-
duction chemotherapy is not associated with improved OS 
in patients with NPC in both unmatched cohort and matched 
cohort. Patients with more advanced disease (T4 and N3) 
and patients with lower education had a higher likelihood 
of receiving induction chemotherapy. Additionally, pa-
tients receiving induction therapy also were more likely to 
be treated with <70 Gy. On multivariable analysis, patients 
with higher T- stage, higher N- stage, higher comorbidities, 
and patients treated with <70 Gy were all predictive of 
lower OS.
The effect of adding induction therapy in NPC is con-
troversial. However, without a major randomized study pro-
viding physicians with any sort of direction in regards to 
induction therapy, the use of induction therapy has remained 
constant over the last decade as seen in this study. Based on 
Univariable analysis Multivariable analysis
OR (95% CI) P- value OR (95% CI) P- value
County type
Metro Ref Ref
Urban 1.11 (0.89- 1.39) .36 NS
Rural 1.83 (.04- 3.21) .04 NS
Clinical T stage
T1 Ref Ref
T2 0.99 (0.79- 1.23) .91 NS
T3 1.26 (1.00- 1.60) .05 NS
T4 1.80 (1.47- 2.22) <.001 1.90 (1.46- 2.48) <.001
Clinical N stage
N0 Ref Ref
N1 0.96 (0.77- 1.20) .74 NS
N2 1.17 (0.95- 1.45) .12 NS
N3 1.99 (1.51- 2.62) <.001 2.47 (1.72- 3.56) <.001
RT Dose
≥7000 cGy Ref Ref
<7000 cGy 1.31 (1.12- 1.52) .001 1.28 (1.05- 1.55) .02
T A B L E  2  (Continued)
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T A B L E  3  Univariable and multivariable analysis for factors predictive of overall survival
Univariable analysis Multivariable analysis
HR (95% CI) P- value HR (95% CI) P- value
Age
Continuous 1.04 (1.03- 1.04) <.001 1.03 (1.02- 1.04) <.001
Sex
Male Ref Ref
Female 0.94 (0.84- 1.05) .30 NS
Year of diagnosis
2004 Ref Ref
2005 1.23 (0.98- 1.55) .08 NS
2006 1.29 (1.02- 1.62) .03 NS
2007 1.14 (0.90- 1.44) .28 NS
2008 1.25 (0.99- 1.58) .06 NS
2009 1.11 (0.88- 1.42) .38 NS
2010 1.12 (0.88- 1.42) .36 NS
2011 1.15 (0.90- 1.47) .28 NS
2012 0.98 (0.75- 1.27) .87 NS
2013 1.10 (0.85- 1.44) .46 NS
2014 0.97 (0.72- 1.30) .82 NS
Charlson index
0 Ref Ref
1 1.62 (1.40- 1.86) <.001 1.26 (1.08- 1.46) .003
2 2.23 (1.73- 2.88) <.001 1.52 (1.16- 1.98) .002
Race
White Ref Ref
African American 0.90 (0.78- 1.04) .16 NS
Other 0.54 (0.47- 0.62) <.001 0.61 (0.52- 0.72) <.001
Facility type
Academic Ref Ref
Non Academic 1.07 (0.96- 1.19) .21 NS
Facility location
East Ref Ref
Central 1.09 (0.97- 1.22) .16 NS
West 1.01 (0.88- 1.17) .85 NS
Insurance status
Private Ref Ref
Medicaid or Other Govt 1.66 (1.44- 1.92) <.001 1.59 (1.35- 1.87) <.001
Medicare 2.69 (2.39- 3.02) <.001 1.52 (1.30- 1.78) <.001
Uninsured 1.71 (1.40- 2.10) <.001 1.62 (1.29- 2.03) <.001
Education level
High Ref Ref
Low 1.30 (1.17- 1.43) <.001 NS
Income level
High Ref Ref
Low 1.39 (1.26- 1.54) <.001 NS
(Continues)
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the patterns of care analysis, younger patients and patients 
with T4 and N3 disease were more likely to receive induction 
therapy. The use of induction therapy in younger patient is 
likely due to the fact that they are better able to tolerate the 
additional cycles of chemotherapy compared to older adults. 
The use of induction therapy in T4 and N3 is likely to reduce 
the target volumes for the definitive chemoradiation therapy. 
Studies have shown that use of induction therapy successfully 
reduces the target volumes of RT in order to avoid overdos-
ing of critical neurological structures and reduce RT related 
toxicities.16,17 For that reason, it is not surprising that we see 
higher use of induction therapy in these patients with very 
advanced disease.
A recent meta- analysis based on individual patient data 
showed a survival benefit associated with concurrent CRT, 
however, it failed to show a survival benefit of induction 
chemotherapy.5,11 Here, we show that induction chemo-
therapy is not an independent predictor of OS. A phase II 
trial of induction cisplatin, epirubicin, and paclitaxel fol-
lowed by concurrent CRT vs concurrent CRT alone did not 
significantly improved OS or progression free survival.18 
Similarly, a randomized phase II/III trial evaluating induc-
tion gemcitabine, carboplatin, and paclitaxel followed by 
concurrent CRT vs concurrent CRT alone showed no sig-
nificant improvement in OS or distant failure- free survival 
with the addition on induction regimen.19 However, these 
findings have not been corroborated by several other trials. 
A recent randomized phase III study comparing induction 
Univariable analysis Multivariable analysis
HR (95% CI) P- value HR (95% CI) P- value
County type
Metro Ref Ref
Urban 1.34 (1.16- 1.53) <.001 NS
Rural 1.21 (0.81- 1.82) .35 NS
Clinical T stage
T1 Ref Ref
T2 1.35 (1.17- 1.57) <.001 1.29 (1.10- 1.52) .002
T3 1.62 (1.38- 1.90) <.001 1.62 (1.37- 1.93) <.001
T4 2.19 (1.90- 2.52) <.001 2.32 (1.98- 2.71) <.001
Clinical N stage
N0 Ref Ref
N1 0.71 (0.62- 0.82) <.001 NS
N2 0.86 (0.76- 0.98) .02 NS
N3 1.40 (1.17- 1.67) <.001 1.84 (1.51- 2.24) <.001
RT dose
≥7000 cGy Ref Ref
<7000 1.16 (1.05- 1.28) .004 1.13 (1.01- 1.25) .03
Treatment
ChemoRT Ref Ref
Induction + ChemoRT 1.05 (0.91- 1.22) .5 NS
T A B L E  3  (Continued)
F I G U R E  2  Overall survival in patients with nasopharyngeal 
carcinoma receiving either ≥70 Gy or <70 Gy of radiation therapy
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docetaxel, cisplatin, and fluorouracil (TPF) followed by 
concurrent CRT vs concurrent CRT alone showed an im-
proved 3- year OS with a HR of 0.54 (95% CI 0.36- 0.95, 
P = .02).8 Similarly, a randomized phase II trial comparing 
induction docetaxel and cisplatin followed by concurrent 
CRT vs concurrent CRT alone showed a significantly in-
creased 3- year OS (HR 0.24; 95% CI 0.08- 0.73, P = .01), 
as well as a trend towards improved progression- free sur-
vival and distant control.20
It has been postulated that some induction studies have 
largely been negative due to the use of ineffective induc-
tion regimen, high treatment- related death, and poor pa-
tient selection. For example, induction chemotherapy may 
only be beneficial in patients with high- risk disease, such 
as T3- 4 or N2- 3. The authors of the trials with positive 
results with induction therapy state that it has been the use 
of more effective induction regimen, such as TPF chemo-
therapy, as well as inclusion of only patients with high risk 
F I G U R E  3  Overall survival in patients with nasopharyngeal carcinoma receiving induction chemotherapy or concurrent chemoradiation. 
A, Represents the whole cohort, unmatched. B, Represents the whole cohort, matched. C, Represents high risk patients defined as T3- 4N1 or 
TanyN2- 3, unmatched. D, Represents high risk patients defined as T3- 4N1 or TanyN2- 3, matched
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disease that has resulted in a significant OS benefit with 
the use of induction chemotherapy.8,21-23 We performed a 
subset analysis on patients with high risk disease and found 
no significant survival advantage with the use of induc-
tion chemotherapy even in the most advanced stage NPC 
(ie T3- 4N1 or TanyN2- 3). Additionally, when stratified by 
individual T- and N- stage, we also did not find an improved 
survival even for the most aggressive NPC (ie T4 or N3). 
On multivariable analysis, we did see that T4 and N3 tu-
mors were more likely to receive induction therapy, though 
no survival difference was noted when stratifying by these 
stages. Another important aspect of whether induction che-
motherapy is effective or not, is the individual components 
that make up the induction regimen. For example, several 
studies have shown that TPF compared to PF is more ef-
fective regimen in the induction setting.21,22,24 However, 
due to the limitations of the database that was used in this 
study, we are unable to draw any conclusions regarding the 
use of various chemotherapy regimens and its effect on OS. 
Several randomized trials assessing various induction che-
motherapy regimens are currently underway and will assist 
in confirming the most optimal induction regimen.25 It is 
believed that induction therapy may have more of a role 
with WHO type 2/3 tumors compared to WHO type 1.26,27 
However, in the present study, no differences in OS were 
observed with induction therapy in either of the two types. 
Though, it should be noted that only ~25% of the patients 
had appropriate information provided to group them as 
WHO type 1 vs WHO type 2/3. As such, no firm conclu-
sions can be drawn with each histological subtype.
Our study also shows that on multivariable analysis, RT 
dose ≥70 Gy is associated with an improved OS. This is 
consistent with several prior studies which have also shown 
70 Gy to be an optimal dose for NPC, resulting in improved 
local control and OS, especially when combined with con-
current chemotherapy.28-30 Interestingly, on multivariable 
analysis, we find that in this cohort, patients receiving in-
duction chemotherapy were in fact less likely to receive 
≥70 Gy. This may result in poor local control, which may 
negate the improved distant control with induction ther-
apy thereby resulting in equivocal OS. Studies have shown 
that patients receiving induction therapy are more likely to 
experience grade 3 or 4 toxicity, especially hematological 
toxicity.8 It is, therefore, possible that these toxicities are 
inhibiting these patients from receiving curative dose of 
RT. As high as 8% treatment- related deaths have been ob-
served in patients receiving induction therapy.24 Similarly, 
patients receiving induction therapy are also less likely to 
complete the full dose of concurrent cisplatin with RT.23 
It has been shown that total dose of cisplatin administered 
with concurrent RT is associated with local control and 
OS.31 In the a recent phase III randomized trial of induction 
TPF and concurrent CRT alone, it was noted that only 30% 
in the induction group vs 56% in the concurrent CRT com-
pleted all three cycles of concurrent cisplatin.8 The NCDB 
does not report on the number of cycles of chemotherapy 
administered, however, based on prior randomized studies, 
it is possible that the patients in the induction group did 
not complete all three cycles of concurrent cisplatin. These 
findings are also supported in induction studies DECIDE 
and PARADIGM for other head and neck sites where the 
induction arm had significantly more adverse events com-
pared to the concurrent CRT alone arm. These studies also 
did not find an OS benefit with induction therapy.32,33
The findings of this study need to be interpreted with the 
understanding of the limitations that are associated with the 
use of NCDB data. NDCB analyses are retrospective in na-
ture and may be confounded by selection bias. In addition, 
the findings of the study should be considered as associa-
tions, and not interpreted as cause and effect. We performed 
multivariable analysis and IPTW- adjusted analysis to min-
imize the selection bias, however, additional unaccounted 
biases may still persist. Furthermore, plasma Epstein- Barr 
virus DNA load, a known prognostic marker,34 is not a coded 
variable in the NCDB and missing from our analyses. Local 
control and treatment related toxicities are also unavailable in 
the NCDB. Additionally, the use of adjuvant chemotherapy 
(after concurrent CRT) was not documented in the database, 
and for that reason, unaccounted for in the multivariable 
analysis. And lastly, the induction chemotherapy regimens 
used in this cohort are likely very heterogeneous based on 
varying treatment practices around the United States. NCDB 
does not identify the individual components of induction che-
motherapy utilized, which is a major limitation of this study. 
Nevertheless, this study sheds important information on the 
debate of induction chemotherapy for NPC in a large national 
cohort.
In conclusion, this study suggest that compared to concur-
rent CRT alone, induction chemotherapy followed by concur-
rent CRT is not associated with improved OS in NPC. This 
finding also holds true even in advanced NPC such as T3- 
4N1 or N2- 3 disease. Additionally, patients receiving induc-
tion chemotherapy are more likely to be treated with lower 
doses of RT potentially resulting in poor local control, which 
may be negating the beneficial effects of improved distant 
control with induction chemotherapy. Future clinical trials 
currently underway are anticipated to answer many questions 
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